AT
Allyx Therapeutics
United States · Biotech
Allyx Therapeutics develops investigational oral medicines intended to protect synapses in Alzheimer’s disease and other neurodegenerative disorders.
Product and customers
Allyx Therapeutics develops oral small molecule therapies for neurodegenerative disease. Its research focuses on protecting synapses from the effects of toxic misfolded proteins.
The New Haven biotechnology company is advancing its lead candidate ALX-001 through clinical development. Its programmes address Alzheimer’s disease and Parkinson’s disease.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Equity and warrant offering | $27.9M | Participants not disclosed |